MacroGenics Announces Leadership Transition
October 30, 2024 07:30 ET
|
MacroGenics, Inc.
Scott Koenig, M.D., Ph.D., to step down as President and CEOBoard to initiate search process to identify new CEO ROCKVILLE, MD, Oct. 30, 2024 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ:...
MacroGenics Announces Date of Third Quarter 2024 Financial Results Conference Call
October 29, 2024 16:30 ET
|
MacroGenics, Inc.
ROCKVILLE, MD, Oct. 29, 2024 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing, manufacturing and commercializing innovative antibody-based...
MacroGenics Announces Updated Efficacy & Safety Data from TAMARACK Phase 2 Study of Vobra Duo in mCRPC Patients at ESMO Congress 2024
September 15, 2024 03:00 ET
|
MacroGenics, Inc.
Encouraging antitumor activity demonstrated with vobra duo as measured by 6-month landmark rPFS rate and ORRPatients remained on vobra duo through a median of 6 doses (ranging up to 12), representing...
MacroGenics Announces TAMARACK Phase 2 Data Presentation at ESMO Congress 2024
September 08, 2024 19:10 ET
|
MacroGenics, Inc.
ROCKVILLE, MD, Sept. 08, 2024 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a biopharmaceutical company focused on discovering, developing, manufacturing and commercializing innovative...
MacroGenics Provides Update on Corporate Progress, Second Quarter 2024 Financial Results
August 06, 2024 16:01 ET
|
MacroGenics, Inc.
Upcoming poster presentation of protocol-defined TAMARACK Phase 2 mCRPC study data at ESMO in SeptemberReceived $100.0 million in milestones related to Incyte’s advancement of ZYNYZ®...
MacroGenics Provides Vobramitamab Duocarmazine Update
July 30, 2024 16:10 ET
|
MacroGenics, Inc.
Abstract of clinical data accepted for poster presentation at ESMO Congress 2024 in SeptemberESMO poster to include protocol-defined TAMARACK Phase 2 mCRPC study data, including pre-defined landmark...
MacroGenics Announces Achievement of $100 Million in Milestones Related to Retifanlimab Collaboration with Incyte
July 30, 2024 16:01 ET
|
MacroGenics, Inc.
ROCKVILLE, MD, July 30, 2024 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a biopharmaceutical company focused on discovering, developing, manufacturing and commercializing innovative...
MacroGenics to Participate in Upcoming Investor Conference
June 11, 2024 07:45 ET
|
MacroGenics, Inc.
ROCKVILLE, MD, June 11, 2024 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing, manufacturing and commercializing innovative monoclonal...
MacroGenics to Participate in Upcoming Investor Conferences
May 13, 2024 07:30 ET
|
MacroGenics, Inc.
ROCKVILLE, MD, May 13, 2024 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing, manufacturing and commercializing innovative monoclonal...
MacroGenics Provides Update on Corporate Progress, First Quarter 2024 Financial Results and Interim TAMARACK Phase 2 Study Data
May 09, 2024 16:01 ET
|
MacroGenics, Inc.
Presentation of interim TAMARACK Phase 2 study data: updated safety and preliminary efficacy of vobra duo in mCRPC patientsConference call scheduled for today at 4:30 p.m. ET ROCKVILLE, Md., May 09,...